The CDC has established a guideline stating that if a patient is observed or suspected of receiving an injection into vascular access lines during their inpatient admission, they should be excluded from CLABSI surveillance. This exclusion can result in significant cost savings for hospitals, as they are not held responsible for the occurrence of a CLABSI in such cases.